Insider Selling: CytomX Therapeutics, Inc. (NASDAQ:CTMX) SVP Sells 19,512 Shares of Stock

CytomX Therapeutics, Inc. (NASDAQ:CTMX) SVP Marcia Belvin sold 19,512 shares of the firm’s stock in a transaction on Tuesday, March 18th. The shares were sold at an average price of $0.60, for a total transaction of $11,707.20. Following the completion of the transaction, the senior vice president now directly owns 248,636 shares of the company’s stock, valued at approximately $149,181.60. This trade represents a 7.28 % decrease in their ownership of the stock. The transaction was disclosed in a filing with the SEC, which is available through the SEC website.

CytomX Therapeutics Trading Up 0.1 %

Shares of NASDAQ:CTMX opened at $0.67 on Friday. CytomX Therapeutics, Inc. has a 12 month low of $0.56 and a 12 month high of $5.85. The company has a market capitalization of $53.41 million, a price-to-earnings ratio of 3.92 and a beta of 1.05. The firm’s 50-day moving average is $0.76 and its 200 day moving average is $0.98.

CytomX Therapeutics (NASDAQ:CTMX) last released its earnings results on Thursday, March 6th. The biotechnology company reported $0.22 EPS for the quarter, beating analysts’ consensus estimates of ($0.23) by $0.45. CytomX Therapeutics had a negative return on equity of 41.47% and a net margin of 10.96%. The firm had revenue of $38.09 million for the quarter, compared to analysts’ expectations of $13.53 million. As a group, equities analysts forecast that CytomX Therapeutics, Inc. will post -0.05 EPS for the current fiscal year.

Analyst Upgrades and Downgrades

A number of brokerages have commented on CTMX. HC Wainwright reissued a “neutral” rating on shares of CytomX Therapeutics in a research note on Friday, March 7th. Wedbush reissued an “outperform” rating and set a $5.00 price objective on shares of CytomX Therapeutics in a research note on Friday, March 7th. Finally, StockNews.com raised CytomX Therapeutics from a “hold” rating to a “buy” rating in a research note on Monday, March 10th. Three equities research analysts have rated the stock with a hold rating and four have given a buy rating to the company’s stock. Based on data from MarketBeat.com, the stock has an average rating of “Moderate Buy” and an average price target of $5.02.

Institutional Trading of CytomX Therapeutics

A number of hedge funds and other institutional investors have recently bought and sold shares of CTMX. Formidable Asset Management LLC boosted its stake in shares of CytomX Therapeutics by 55.5% during the fourth quarter. Formidable Asset Management LLC now owns 382,529 shares of the biotechnology company’s stock valued at $394,000 after purchasing an additional 136,528 shares during the period. Velan Capital Investment Management LP bought a new stake in CytomX Therapeutics during the 4th quarter valued at about $36,000. Tidal Investments LLC lifted its holdings in CytomX Therapeutics by 55.5% during the 4th quarter. Tidal Investments LLC now owns 382,529 shares of the biotechnology company’s stock valued at $394,000 after buying an additional 136,528 shares in the last quarter. Point72 Asset Management L.P. purchased a new stake in CytomX Therapeutics in the 4th quarter valued at about $2,730,000. Finally, Prosight Management LP grew its stake in CytomX Therapeutics by 29.2% in the 4th quarter. Prosight Management LP now owns 3,905,000 shares of the biotechnology company’s stock worth $4,022,000 after acquiring an additional 882,891 shares in the last quarter. Hedge funds and other institutional investors own 67.77% of the company’s stock.

About CytomX Therapeutics

CytomX Therapeutics, Inc, an oncology-focused biopharmaceutical company, focuses on developing novel conditionally activated biologics localized to the tumor microenvironment. The company utilizes conditional activation platform technology for oncology biologics research and development comprising the validation of targets for antibody-drug conjugates (ADCs), opening therapeutic window for novel T-cell engagers (TCEs) targeting solid tumors, and increasing the therapeutic index for immune modulators, such as cytokines; and PROBODY platform in preclinical research in areas outside of oncology.